Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Molecular Targets Open for Regulation by the gut flora – New Avenues for improved Diet to Optimize European health (TORNADO)

Framework: FP7 — Cooperation
Programme: Food, Agriculture and Fisheries, and Biotechnology
Destination: Fork to farm: Food (including seafood), health and well being
Action type: Collaborative project
Countries involved: Sweden,France,United Kingdom,Finland,Sweden,Switzerland,Netherlands,Sweden,Denmark,Hungary,Germany,Hungary,France,Denmark,Germany,Estonia
Call:  (FP7-KBBE-2007-2A, 2007)
Start date: 2009-09-01
End date: 2014-08-31
Duration (months): 60.0
Total project cost (EUR): 7771046.13
EU funding (EUR): 5895601.0
Participants: 23
Project status: CLOSED

Europe is facing major diet related health problems. Attitudes to eating habits have to be changed and the benefits of alternative treatment regimes substantiated. This can only be achieved by providing guidelines regulating health claims based on scientific data. Thus, there is a unique opportunity to use gut flora in potential treatment regimes and as a preventive target for major diet related health problems. TORNADO consortium proposes a systemic and comprehensive mechanistic approach to deliver scientific data that can be compiled as guidelines for European authorities. TORNADO will determine the influence of diet on the gut flora and highlight the impact of gut flora on the immune system/other organ systems. TORNADO aims to investigate molecular targets that are subject to regulation by gut flora and diet that sustain health. This will be done by an increasing level of specificity, from (1) investigations of dietary habits and health in population cohorts, through (2) intervention studies in humans and animals and (3) analyses of the intestine and immune system, and also organs like adipocyte tissue, liver & brain, to pinpointing the impact of dietary influence on (4) cells and (5) potential functional molecular targets. TORNADO will deliver data that can be used to recommend biomarkers for evaluating effects of diet or microbes; refute, substantiate or improve health claims of existing products; generate novel functional food products. TORNADO's approach of microbe-to-mouse-to-man validation of dietary influence will enable more solid evidence for health claims and provide concrete deliverables e.g. Roadmaps to Health, Tailor-made Health-monitoring. Continuous state-of-the-art dissemination programs will increase impact. TORNADO's program will accelerate future design of personalized functional food for specific target groups. The evidence-based data delivered by TORNADO will have long lasting effects on health among European citizens well beyond 2012.

Keywords: intestinal microflora,health biomarkers,functional foods,immunology,cellular microbiology,nutrition,diet,host-microbe interaction
Metastatic tumours facilitated by hypoxic tumour micro-environments (METOXIA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Norway,Netherlands,United Kingdom,Netherlands,United Kingdom,Denmark,United Kingdom,Italy,Sweden,Spain,Germany,France,Germany,Lithuania,Slovakia
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2014-07-31
Duration (months): 66.0
Total project cost (EUR): 16038623.2
EU funding (EUR): 11998300.0
Participants: 21
Project status: CLOSED

Recent research suggests that the hypoxic micro-environment of tumours is one of the major drivers of metastatic spread of cancer. Furthermore, hypoxic tumour micro-environments may result in treatment resistance of cancer cells, therefore causing a double effect of reducing the potential of a successful treatment of the cancer patient. This project seeks to clarify the roles and functions of the hypoxic tumour micro-environment in relation to the survival of solid tumours likely to metastasise. We will gain new knowledge about molecular mechanisms behind hypoxia-driven metastasis, like the epithelial-mesenchymal transition (EMT) by several routes: (a): mechanisms related to cell growth- and cell proliferation (UPR, mTOR, CA9, HIF, Notch, and VHL), (b): angiogenesis and lymphangiogenesis, (c): metabolism and pH-regulation (d): the handling of reactive oxygen species (ROS). We will generate animal models for the study of the role of hypoxia in metastases and develop a bio-bank of tumour and blood samples for molecular diagnostic studies. We will identify and develop advanced imaging techniques and biomarkers and identify micro-metastases in bone marrow of patients to assist in the selection of appropriate stratification of the actual primary tumour’s and metastases’ micro-environmental conditions. We will also create a machine-learning based classifier of tumour hypoxia. The consortium has the necessary expertise to perform proof-of-principle clinical testing of new treatment strategies. We will thus perform clinical tests of new drugs developed to attack the regulatory mechanisms selected from the pre-clinical work and possible synergisms of combined treatments. We will also test new radiotherapy strategies for treatment of primary as well as metastatic tumours. Cancer types chosen for clinical studies are non-small-cell lung carcinoma, squamous cell carcinoma of the larynx, prostate cancer, primary breast cancer and rectal cancer.

Keywords: hypoxia,metastasis,biomarkers,micro-environment,ca9-inhibitors,patient stratification,oxygenation.
New Brazilian Bureau for Enhancing the International Cooperation with European Union (BB.BICE)

Framework: FP7 — Capacities
Programme: Activities of International Cooperation
Destination: Bilateral coordination for the enhancement and development of S&T Partnerships
Action type: Coordination and support actions
Countries involved: Brazil
Call:  (FP7-INCO-2007-2, 2007)
Start date: 2008-10-01
End date: 2011-12-31
Duration (months): 39.0
Total project cost (EUR): 560523.6
EU funding (EUR): 499800.0
Participants: 1
Project status: CLOSED

This proposal is mainly a continuation of a successful initiative that was supported by the 6th Framework Program. The Project B.Bice (the acronym for Brazilian Bureau to Enhance the International Cooperation between Brazil and Europe) initiated its activities on October 2005 with the aim of fostering and enhancing the cooperation in Science, Technology and Innovation – ST&I between Brazil and the European Union. The Bureau acted as a mechanism to improve the participation of Brazil in the 7th Framework Program of Research and Development, through the organization and dissemination of information concerning cooperation research priorities, the identification of financial mechanisms for supporting this cooperation, and the search of Brazilian and European partners for setting up project proposals. Besides, B.Bice helped the Brazilian scientific and technological institutions, and the technological based enterprises in the preparation and negotiation process of project proposals to be submitted to the European Commission. Another additional function of B.Bice was to keep a permanent contact and flow of information with the other three Latin American countries with bilateral cooperation agreement in ST&I with the EU – Argentina, Chile, and Mexico – in order to look for a coordination and integration of the four countries when preparing and presenting project proposals in response to calls. Taking into account the advances made by the Project B.Bice during its two years of functioning (October 2005-September 2007), the intention of this proposal is to keep the Bureau active for an additional period of three years, in order to consolidate the participation of the Brazilian Research institutions and technological based enterprises in the international cooperation activities with the European Union.

Keywords: cooperation,articulation,priorities,support,dissemination,information.
New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian subcontinent (KALADRUG-R)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,United Kingdom,Germany,Germany,United Kingdom,India,Nepal
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2013-04-30
Duration (months): 54.0
Total project cost (EUR): 3972950.8
EU funding (EUR): 2999998.0
Participants: 10
Project status: CLOSED

Visceral leishmaniasis (VL), one of the most-neglected infectious diseases, has an annual incidence of 500,000 cases. Early treatment is a major pillar of the current program for VL elimination on the Indian sub-continent. However, the arsenal of available drugs is very limited, and their use is jeopardized by drug resistance. Combination regimens for VL are under clinical development, but it will take several more years to change the drug policy. Meanwhile, the effectiveness of current drugs needs to be safeguarded in order to cure patients and ensure unremitting sustainment of VL control. For this, the uninterrupted supply of quality drugs, the promotion of treatment compliance and, the monitoring of treatment effectiveness and of drug resistance will be pivotal. The latter demands improved knowledge and know-how, hence clinical and laboratory research are urgently needed to support the drug policy of the VL elimination program. The present multi-disciplinary proposal addresses these needs: we aim to develop, evaluate and disseminate new tools for the assessment of drug resistance in L. donovani as well as innovative methodologies for monitoring Kala-Azar treatment effectiveness under routine conditions.

Keywords: visceral leishmaniasis,india,nepal,drug resistance,antimonials,miltefosine,paromomycin
Linking Scientific Computing in Europe and the Eastern Mediterranean (LINKSCEEM)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to policy development and Programme implementation
Action type: Coordination and support actions
Countries involved: Cyprus,Switzerland,Greece,Israel,United States,Germany,Netherlands,Jordan
Call:  (FP7-INFRASTRUCTURES-2007-2, 2007)
Start date: 2008-04-01
End date: 2010-01-31
Duration (months): 22.0
Total project cost (EUR): 747164.0
EU funding (EUR): 570000.0
Participants: 8
Project status: CLOSED

The Cyprus Institute is developing a Computation-based Science and Technology Research Centre (CSTRC) that will include a high-performance computing (HPC) facility on a scale expected to be in the tens of teraflops, with an associated research and educational centre devoted to computational science. The CSTRC will be designed primarily to serve the needs of Cyprus and the Eastern Mediterranean region. This Support Action aims to ensure that in its planning and early development phases the CSTRC develops strong anchors in both the European ICT infrastructure and the Eastern Mediterranean scientific community, thereby helping to build scientific and technological bridges between Europe and the Middle East and to narrow the digital gap between the Eastern Mediterranean and the Western World. This will be achieved through the action of a consortium of European and US leaders in the fields of HPC and computational science and of prominent Eastern Mediterranean research institutions. The consortium will conduct studies, prospective work and outreach activities relevant to the integration of CSTRC in the EU HPC landscape and to the attainment of its regional dimension. Planned actions include the assessment of needs for computational resources within the scientific community of Cyprus and the Eastern Mediterranean, the coordination of HPC resources and their integration in Europe and the region, the planning of the access of users, the preparation of research and educational programmes in computational science, as well as a feasibility study for the amelioration of the network connectivity in the region. Dissemination and outreach actions, including an International Conference and several users workshops, will also be conducted. All of these will bring significant contributions to the EC’s objectives in the fields of e-science, e-infrastructures and their integration on a European and regional Eastern Mediterranean scales.

Keywords: high performance computing,computational science,e-infrastructure,grids,expert studies,hpc resources,climate modelling,digital heritage,eastern mediterranean,international cooperation
European Paediatric Oncology Off-Patent Medicines Consortium (EPOC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,United Kingdom,Germany,Italy,France,Spain
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2013-10-31
Duration (months): 57.0
Total project cost (EUR): 2575594.02
EU funding (EUR): 1997862.0
Participants: 11
Project status: CLOSED

Cancer chemotherapy has a key role in the successful treatment of a number of childhood cancers. Nevertheless, at least 20% of patients are not cured by current therapies and a significant number experience debilitating toxicities. Given the high cure rates and potential life-span of survivors of childhood cancer, it is particularly important to minimize the impact of potential chronic toxicities. For several of the most widely-used drugs, little is known about their pharmacokinetics and metabolism in children, particularly very young children (&lt;3 years). There are many examples where such knowledge has been used to optimize the use of chemotherapeutic drugs, both to avoid toxicity and to maximize the therapeutic effect. The need for further research to investigate these drugs in children is acknowledged in the Priority List for Studies into Paediatric Medicinal Products, issued by the EMEA. Doxorubicin is on this list and is one of the most important drugs used in the treatment of childhood cancers. Several national groups have been successful in studying the pharmacology of drugs used in paediatric oncology. However, in order to recruit sufficient patient numbers for meaningful studies it is necessary to establish a wider group, bringing together the successful elements of established national organizations. The EPOC group combines leading pharmacologists, paediatric oncologists, regulatory organizations and a management structure which will successfully deliver data of appropriate quality on which to base future clinical use of this drug and to meet the demands of the EMEA priority list. Such data will form the basis of future applications for Paediatric Usage Marketing Authorization for doxorubicin. The overall aim of the consortium is to provide data that will guide the optimal use of this drug in the clinic, and also meet the regulatory requirements of the EMA.

Keywords: cancer children pharmacokinetics pharmacogenetics
Massive Digital sequencing by binary DNA (DIGITAL SEQUENCING)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Sweden,France,Norway,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-12-01
End date: 2014-05-31
Duration (months): 54.0
Total project cost (EUR): 5169871.51
EU funding (EUR): 3000000.0
Participants: 5
Project status: CLOSED

DNA sequencing costs have fallen more than 50-fold over the past decade, driven part by tools, technology and process improvements made during the Human Genome Project. However, it still costs around $10 million to sequence 3 billion base pairs - the amount of DNA found in the genomes of humans and other mammals. 1st generation sequencing platforms, which are based upon capillary electrophoresis and fluorescence detection, have been around since 1992. Due to poor price/performance parameters several initiatives have been launched to facilitate a replacement of this sequencing technology. Most notably is the US National Institute of Health with the goal of developing 2nd and 3rd generation technologies that can read a human genome for $100.000 and $1.000 respectively. To date four vendors have introduced 2nd generation platforms to the market and they have the capacities of sequencing between 0,5 to 2 Gb per 24 hours. The main limitation for improved price/performance of 2nd generation platforms is that they are based on an expensive CCD-camera set up. As a consequence new and radical approaches are required to meet the $1.000 genome goal. This proposal aims to develop a high-throughput low cost 3rd generation DNA sequencing instrument, by deploying novel DNA preparation methods and read-out technologies. The potential instrument output is 200-300Gbp raw sequence per run, which allows for whole genome sequencing on a mass scale. A consortium of five European partners with multidisciplinary expertise has been established to reach the overall objective of this ambitious project.

Keywords: development of a 3rd generation dna sequencing platform - digital sequencer.
The antiretroviral roll out for HIV in India - strengthening capacity to promote adherence and patient follow-up in the context. (HIVIND)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,India,Viet Nam,Finland,Sweden
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2014-04-30
Duration (months): 66.0
Total project cost (EUR): 3881494.95
EU funding (EUR): 2946420.0
Participants: 6
Project status: CLOSED

India is a nation of contrasts. The economy is modernizing, but the culture is traditional. Different provinces experience the HIV epidemic differently; even in high-prevalence areas, the epidemic reflects diverse social, cultural, religious, & sexual practices. This proposal focuses on 2 high prevalence provinces. As the antiretroviral (ART) program is scaled up, adherence is a key issue that needs to be addressed (as it is a key determinant of resistance, which has public health consequences). With limited affordable second-line regimens & restricted laboratory monitoring in low-income settings, optimal adherence to first-line regimens is essential. The study is a randomized controlled trial of an approach using a contextually relevant intervention (mobile telephones) to influence ART adherence in 600 ART naïve, HIV+ Indian patients eligible for ART, in Karnataka and Tamil Nadu. The conventional existing approach (as in the national guidelines) will be compared with an intervention in which the patient is provided adherence support using a mobile telephone interface. The study besides assessing the effect of intervention on adherence, will also provide data on the proportion of Indian patients failing first line ART. A study of factors associated with adherence, hitherto unstudied in India will be done. In addition the incidence and manifestations of opportunistic infections, immune reconstitution syndrome & adverse drug events will be described. The use of validated low-cost tests that optimize monitoring, are necessary here. Viral load is rarely used to monitor treatment because it is expensive. Instead falling CD4 counts are used. This usually occurs months/years after virological failure (increasing load); patients could have accumulated enough resistant mutations in this time to render other drugs useless. Using an affordable load test (evaluated in this study) will allow earlier detection of failure in this setting, thus having public health implications. Cost effectiveness will be studied. The project has policy implications for India and other low income settings.

Keywords: india,adherence,randomized control trial,monitoring,load,resistance,phenotypic
Coordination, rationalisation and integration of antimalarial drug discovery initiatives (CRIMALDDI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: United Kingdom,Switzerland,Switzerland,Germany,Italy,France,Cameroon,South Africa
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2011-06-30
Duration (months): 29.0
Total project cost (EUR): 560747.69
EU funding (EUR): 500000.0
Participants: 9
Project status: CLOSED

Antimalarial drug discovery and development initiatives globally are fragmented and uncoordinated. We have brought together key organisations including MMV, WHO and AntiMal, an EU-funded FP6 Integrated Project represented by its coordinating institution and a number of academic malaria researchers, to resolve this problem through a logical series of meetings, conferences, workshops and dissemination strategies. The Gates Foundation will be involved as an invited participant. The action will co-ordinate leading European malaria research initiatives in antimalarial drug discovery and development, co-ordinate the European effort with international initiatives, engage industry and provide guidance on standardisation of core requirements of regulatory drug development. This will contribute towards generating global priorities and prepare the European antimalarial research agenda for the next decade.

Keywords: malaria,drugs,public private partnerships,coordination
High Throughput Proteomics Systems for Accelerated Profiling of Putative Plasma Biomarkers (PROACTIVE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Sweden,Denmark,United Kingdom,Spain,Sweden
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2011-09-30
Duration (months): 36.0
Total project cost (EUR): 3950800.0
EU funding (EUR): 2989800.0
Participants: 6
Project status: CLOSED

The PROACTIVE consortium will through research and innovation develop the multiplexed proximity ligation assay into a high throughput protein detection and quantification technology along with novel data management and analysis tools. Hundreds of putative biomarkers of the plasma proteome can then be assayed with high sensitivity in minute sample volumes, far surpassing any current capabilities. This consortium combines three SMEs across Europe with synergistic competences in technology development, reagent manufacturing, and software development for data management and analysis. Together with clinical cancer scientists, biostatisticians, and diagnostics industry, these high capacity tools will be evaluated in pilot projects for cancer biomarkers using biobanked samples. Preliminary data in the literature claim improved diagnostics with the use of multiple complementary protein markers. However, there is a lack of suitable high throughput procedures for finding new markers and discovering which markers complement each other into effective diagnostic panels. Better capabilities to diagnose cancer at the early and most curable stages will greatly improve human health and reduce health care costs. Patient stratification is also in need of better diagnostics to facilitate the selection of appropriate patient care. Many clinically used immunoassays capable of diagnosing cancer have been in use for many years as single markers but with limited sensitivity and specificity. No marker can today single-handedly diagnose all cases with desired accuracy for a certain cancer type. Also, the performance of these markers is decreased for the earliest stages of the disease. At the conclusion of this collaborative project, the research and innovation conducted within the consortium will enable the partners to position themselves at the very fore-front of high-throughput biomarker research strengthening their competitiveness in the international arena.

Keywords: biomarker tools,antibody,high throughput,proteomics,biostatistics,cancer